Bloomberg Law News: Patent Reform Bill Risks Higher Drug Prices and Delayed Generics

O’Melveny’s Coke Morgan Stewart authored a byline article in Bloomberg Law News on Tuesday, discussing the downsides of a drug patent reform bill.